Risk  ||| S:0 E:5 ||| NN
of  ||| S:5 E:8 ||| IN
follicular  ||| S:8 E:19 ||| NNS
lymphoma  ||| S:19 E:28 ||| VBP
associated  ||| S:28 E:39 ||| VBN
with  ||| S:39 E:44 ||| IN
BCL2  ||| S:44 E:49 ||| CD
translocations  ||| S:49 E:64 ||| NN
in  ||| S:64 E:67 ||| IN
peripheral  ||| S:67 E:78 ||| JJ
blood  ||| S:78 E:84 ||| NN
Many  ||| S:84 E:89 ||| JJ
adults  ||| S:89 E:96 ||| NNS
have  ||| S:96 E:101 ||| VBP
circulating  ||| S:101 E:113 ||| VBG
lymphocytes  ||| S:113 E:125 ||| NN
with  ||| S:125 E:130 ||| IN
the  ||| S:130 E:134 ||| DT
BCL2  ||| S:134 E:139 ||| JJ
gene  ||| S:139 E:144 ||| NN
translocation  ||| S:144 E:158 ||| NN
characteristic  ||| S:158 E:173 ||| NN
of  ||| S:173 E:176 ||| IN
follicular  ||| S:176 E:187 ||| JJ
lymphoma ||| S:187 E:195 ||| NN
.  ||| S:195 E:197 ||| .
We  ||| S:197 E:200 ||| PRP
therefore  ||| S:200 E:210 ||| RB
conducted  ||| S:210 E:220 ||| VBN
a  ||| S:220 E:222 ||| DT
nested  ||| S:222 E:229 ||| JJ
case-control  ||| S:229 E:242 ||| JJ
study  ||| S:242 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
incident  ||| S:251 E:260 ||| NN
lymphomas  ||| S:260 E:270 ||| NN
with  ||| S:270 E:275 ||| IN
peripheral  ||| S:275 E:286 ||| JJ
blood  ||| S:286 E:292 ||| NN
obtained  ||| S:292 E:301 ||| VBD
a  ||| S:301 E:303 ||| DT
median  ||| S:303 E:310 ||| JJ
4.9  ||| S:310 E:314 ||| CD
years  ||| S:314 E:320 ||| NNS
pre-diagnosis  ||| S:320 E:334 ||| JJ
from  ||| S:334 E:339 ||| IN
the  ||| S:339 E:343 ||| DT
Prostate ||| S:343 E:351 ||| NNP
,  ||| S:351 E:353 ||| ,
Lung ||| S:353 E:357 ||| NNP
,  ||| S:357 E:359 ||| ,
Colorectal  ||| S:359 E:370 ||| NNP
and  ||| S:370 E:374 ||| CC
Ovarian  ||| S:374 E:382 ||| NNP
Cancer  ||| S:382 E:389 ||| NNP
Screening  ||| S:389 E:399 ||| NNP
Trial ||| S:399 E:404 ||| NNP
.  ||| S:404 E:406 ||| .
Overall ||| S:406 E:413 ||| RB
,  ||| S:413 E:415 ||| ,
13  ||| S:415 E:418 ||| CD
of  ||| S:418 E:421 ||| IN
26  ||| S:421 E:424 ||| CD
cases  ||| S:424 E:430 ||| NNS
of  ||| S:430 E:433 ||| IN
lymphoma  ||| S:433 E:442 ||| NN
and  ||| S:442 E:446 ||| CC
14  ||| S:446 E:449 ||| CD
of  ||| S:449 E:452 ||| IN
47  ||| S:452 E:455 ||| CD
controls  ||| S:455 E:464 ||| NNS
had  ||| S:464 E:468 ||| VBD
BCL2  ||| S:468 E:473 ||| CD
major  ||| S:473 E:479 ||| JJ
breakpoint  ||| S:479 E:490 ||| JJ
region  ||| S:490 E:497 ||| NN
( ||| S:497 E:498 ||| -LRB-
MBR ||| S:498 E:501 ||| NNP
)  ||| S:501 E:503 ||| -RRB-
translocations  ||| S:503 E:518 ||| NN
in  ||| S:518 E:521 ||| IN
pre-diagnosis  ||| S:521 E:535 ||| JJ
blood  ||| S:535 E:541 ||| NN
( ||| S:541 E:542 ||| -LRB-
odds  ||| S:542 E:547 ||| JJ
ratio  ||| S:547 E:553 ||| NN
[ ||| S:553 E:554 ||| -LRB-
OR ||| S:554 E:556 ||| NNP
]  ||| S:556 E:558 ||| -RRB-
=  ||| S:558 E:560 ||| SYM
2.8 ||| S:560 E:563 ||| CD
) ||| S:563 E:564 ||| -RRB-
.  ||| S:564 E:566 ||| .
Nine  ||| S:566 E:571 ||| CD
cases  ||| S:571 E:577 ||| NNS
had  ||| S:577 E:581 ||| VBD
BCL2-MBR-positive  ||| S:581 E:599 ||| CD
tumors ||| S:599 E:605 ||| NNS
;  ||| S:605 E:607 ||| :
eight  ||| S:607 E:613 ||| CD
of  ||| S:613 E:616 ||| IN
these  ||| S:616 E:622 ||| DT
nine  ||| S:622 E:627 ||| CD
had  ||| S:627 E:631 ||| VBD
BCL2-MBR  ||| S:631 E:640 ||| CD
translocations  ||| S:640 E:655 ||| NN
in  ||| S:655 E:658 ||| IN
paired  ||| S:658 E:665 ||| JJ
blood  ||| S:665 E:671 ||| NN
versus  ||| S:671 E:678 ||| IN
five  ||| S:678 E:683 ||| CD
of  ||| S:683 E:686 ||| IN
the  ||| S:686 E:690 ||| DT
17  ||| S:690 E:693 ||| CD
with  ||| S:693 E:698 ||| IN
BCL2-MBR-negative  ||| S:698 E:716 ||| CD
tumors  ||| S:716 E:723 ||| NNS
( ||| S:723 E:724 ||| -LRB-
p  ||| S:724 E:726 ||| CD
=  ||| S:726 E:728 ||| SYM
0.01 ||| S:728 E:732 ||| CD
) ||| S:732 E:733 ||| -RRB-
.  ||| S:733 E:735 ||| .
Comparing  ||| S:735 E:745 ||| VBG
both  ||| S:745 E:750 ||| DT
tumor  ||| S:750 E:756 ||| NN
types  ||| S:756 E:762 ||| NNS
to  ||| S:762 E:765 ||| TO
controls ||| S:765 E:773 ||| NNS
,  ||| S:773 E:775 ||| ,
blood  ||| S:775 E:781 ||| NN
BCL2-MBR  ||| S:781 E:790 ||| CD
translocations  ||| S:790 E:805 ||| NNS
had  ||| S:805 E:809 ||| VBD
a  ||| S:809 E:811 ||| DT
strong ||| S:811 E:817 ||| JJ
,  ||| S:817 E:819 ||| ,
statistically  ||| S:819 E:833 ||| RB
significant  ||| S:833 E:845 ||| JJ
association  ||| S:845 E:857 ||| NN
with  ||| S:857 E:862 ||| IN
BCL2-MBR-positive  ||| S:862 E:880 ||| CD
tumors  ||| S:880 E:887 ||| NNS
( ||| S:887 E:888 ||| -LRB-
OR  ||| S:888 E:891 ||| NNP
=  ||| S:891 E:893 ||| SYM
26 ||| S:893 E:895 ||| CD
) ||| S:895 E:896 ||| -RRB-
,  ||| S:896 E:898 ||| ,
but  ||| S:898 E:902 ||| CC
not  ||| S:902 E:906 ||| RB
with  ||| S:906 E:911 ||| IN
BCL2-MBR-negative  ||| S:911 E:929 ||| CD
tumors  ||| S:929 E:936 ||| NNS
( ||| S:936 E:937 ||| -LRB-
OR  ||| S:937 E:940 ||| NNP
=  ||| S:940 E:942 ||| SYM
0.9 ||| S:942 E:945 ||| CD
) ||| S:945 E:946 ||| -RRB-
.  ||| S:946 E:948 ||| .
All  ||| S:948 E:952 ||| DT
eight  ||| S:952 E:958 ||| CD
BCL2-MBR-positive  ||| S:958 E:976 ||| CD
tumors  ||| S:976 E:983 ||| NNS
with  ||| S:983 E:988 ||| IN
pre-diagnosis  ||| S:988 E:1002 ||| JJ
BCL2  ||| S:1002 E:1007 ||| CD
translocations  ||| S:1007 E:1022 ||| NNS
were  ||| S:1022 E:1027 ||| VBD
clonally  ||| S:1027 E:1036 ||| VBN
related  ||| S:1036 E:1044 ||| VBN
to  ||| S:1044 E:1047 ||| TO
these  ||| S:1047 E:1053 ||| DT
circulating  ||| S:1053 E:1065 ||| JJ
cells ||| S:1065 E:1070 ||| NNS
,  ||| S:1070 E:1072 ||| ,
based  ||| S:1072 E:1078 ||| VBN
on  ||| S:1078 E:1081 ||| IN
similarity  ||| S:1081 E:1092 ||| NN
of  ||| S:1092 E:1095 ||| IN
recombination  ||| S:1095 E:1109 ||| JJ
sequences ||| S:1109 E:1118 ||| NN
.  ||| S:1118 E:1120 ||| .
These  ||| S:1120 E:1126 ||| DT
data  ||| S:1126 E:1131 ||| NNS
indicate  ||| S:1131 E:1140 ||| VBP
that  ||| S:1140 E:1145 ||| DT
blood  ||| S:1145 E:1151 ||| NN
BCL2-MBR  ||| S:1151 E:1160 ||| CD
translocations  ||| S:1160 E:1175 ||| NNS
represent  ||| S:1175 E:1185 ||| VBP
lymphoma  ||| S:1185 E:1194 ||| JJ
precursor  ||| S:1194 E:1204 ||| NN
clones  ||| S:1204 E:1211 ||| NNS
with  ||| S:1211 E:1216 ||| IN
malignant  ||| S:1216 E:1226 ||| JJ
potential ||| S:1226 E:1235 ||| NN
.  ||| S:1235 E:1237 ||| .
